Litcius/Paper detail

Synaptic Effects of Palmitoylethanolamide in Neurodegenerative Disorders

Martina Assogna, Francesco Di Lorenzo, Alessandro Martorana, Giacomo Koch

2022Biomolecules24 citationsDOIOpen Access PDF

Abstract

Increasing evidence strongly supports the key role of neuroinflammation in the pathophysiology of neurodegenerative diseases, such as Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Neuroinflammation may alter synaptic transmission contributing to the progression of neurodegeneration, as largely documented in animal models and in patients' studies. In the last few years, palmitoylethanolamide (PEA), an endogenous lipid mediator, and its new composite, which is a formulation constituted of PEA and the well-recognized antioxidant flavonoid luteolin (Lut) subjected to an ultra-micronization process (co-ultraPEALut), has been identified as a potential therapeutic agent in different disorders by exerting potential beneficial effects on neurodegeneration and neuroinflammation by modulating synaptic transmission. In this review, we will show the potential therapeutic effects of PEA in animal models and in patients affected by neurodegenerative disorders.

Topics & Concepts

NeuroinflammationPalmitoylethanolamideNeurodegenerationNeuroscienceNeurochemicalAmyotrophic lateral sclerosisMedicineDementiaBiologyDiseaseInternal medicineReceptorCannabinoid receptorAgonistAlzheimer's disease research and treatmentsParkinson's Disease Mechanisms and TreatmentsCannabis and Cannabinoid Research
Synaptic Effects of Palmitoylethanolamide in Neurodegenerative Disorders | Litcius